Generic drug: valrubicin
Brand name: Valstar
What is Valstar (valrubicin), and how does it work?
Valstar (valrubicin) is a cancer (antineoplastic) medication used to treat bladder cancer.
What is the dosage for Valstar?
For Intravesical Use Only. Do NOT administer by intravenous or intramuscular routes.
Valstar is recommended at a dose of 800 mg administered intravesically once a
week for six weeks. Delay administration at least two weeks after transurethral
resection and/or fulguration.
What drugs interact with Valstar?
No drug interaction studies were conducted.
Is Valstar safe to use while pregnant or breastfeeding?
- Based on findings in animal studies and its mechanism of action, Valstar can cause fetal harm when administered to a pregnant females.
- There are no available data in pregnant females to inform the drug-associated risk.
- There are no data on the presence of valrubicin or its metabolites in human milk, the effects of valrubicin on the breastfed infant, or its effects on milk production.
- Because of the potential for serious adverse reactions in breast-fed infants from valrubicin, advise a lactating female not to breastfeed during treatment with
Valstar and for 2 weeks after the final dose.
Medically Reviewed on 4/2/2021
All sections courtesy of the U.S. Food and Drug Administration
- Yog Yatra: योग करेगा हड्डी के रोगों को दूर, जानिए Baba Ramdev से - April 16, 2021
- Water crisis took toll on Flint adults’ physical, mental health - April 16, 2021
- Bingeing, Stress Snacking: How the Pandemic Is Changing Eating Habits - April 16, 2021
- A method to assess COVID-19 transmission risks in indoor settings - April 16, 2021
- Later School Start Times Mean Better-Rested Kids: Study - April 16, 2021
- हरदा में 26 अप्रैल तक रहेगा कोरोना कर्फ्यू - April 16, 2021
- Ten reasons why the coronavirus is airborne - April 16, 2021
- Your Zip Code Could Help or Harm Your Brain - April 16, 2021
- 10वीं और 12वीं के प्रवेश-पत्रों में 10 मई तक करा सकेंगे संशोधन - April 16, 2021
- Temporal link between medical cannabis for epilepsy and early puberty - April 16, 2021